311 related articles for article (PubMed ID: 30728528)
1. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
2. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon.
Zgheib NK; Akika R; Mahfouz R; Aridi CA; Ghanem KM; Saab R; Abboud MR; Tarek N; El Solh H; Muwakkit SA
Pediatr Blood Cancer; 2017 Jan; 64(1):146-150. PubMed ID: 27577869
[TBL] [Abstract][Full Text] [Related]
3. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
[TBL] [Abstract][Full Text] [Related]
5. The Role of TPMT, ITPA, and NUDT15 Variants during Mercaptopurine Treatment of Swedish Pediatric Patients with Acute Lymphoblastic Leukemia.
Wahlund M; Nilsson A; Kahlin AZ; Broliden K; Myrberg IH; Appell ML; Berggren A
J Pediatr; 2020 Jan; 216():150-157.e1. PubMed ID: 31635813
[TBL] [Abstract][Full Text] [Related]
6. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine.
Khaeso K; Komvilaisak P; Chainansamit SO; Nakkam N; Suwannaying K; Kuwatjanakul P; Hikino K; Dornsena A; Kanjanawart S; Laoaroon N; Vannaprasaht S; Taketani T; Tassaneeyakul W
Drug Metab Pharmacokinet; 2022 Apr; 43():100436. PubMed ID: 35016134
[TBL] [Abstract][Full Text] [Related]
7. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity.
Shah SAV; Paradkar MU; Desai DC; Ashavaid TF
Drug Metab Pers Ther; 2018 Mar; 33(1):57-60. PubMed ID: 29470173
[TBL] [Abstract][Full Text] [Related]
8. Update on thiopurine pharmacogenetics in inflammatory bowel disease.
Roberts RL; Barclay ML
Pharmacogenomics; 2015 Jul; 16(8):891-903. PubMed ID: 26067482
[TBL] [Abstract][Full Text] [Related]
9. Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT.
Kim H; You S; Park Y; Choi JY; Ma Y; Hong KT; Koh KN; Yun S; Lee KH; Shin HY; Lee S; Yoo KH; Im HJ; Kang HJ; Kim JH
Sci Rep; 2021 May; 11(1):9676. PubMed ID: 33958640
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of 6-mercaptopurine in a black Zimbabwean cohort treated for acute lymphoblastic leukaemia.
Chikondowa P; Munkombwe D; Chikwambi Z; Kuona P; Masimirembwa C
Pharmacogenomics; 2023 Jun; 24(8):449-457. PubMed ID: 37248698
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive study of thiopurine methyltransferase genotype, phenotype, and genotype-phenotype discrepancies in Sweden.
Zimdahl Kahlin A; Helander S; Skoglund K; Söderkvist P; Mårtensson LG; Appell ML
Biochem Pharmacol; 2019 Jun; 164():263-272. PubMed ID: 31005613
[TBL] [Abstract][Full Text] [Related]
12. Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.
Desai D; Jena A; Sharma V; Hibi T
Expert Rev Clin Pharmacol; 2023; 16(7):643-653. PubMed ID: 37387532
[TBL] [Abstract][Full Text] [Related]
13. Development of a rapid clinical TPMT genotyping assay.
Burchard PR; Abou Tayoun AN; Lefferts JA; Lewis LD; Tsongalis GJ; Cervinski MA
Clin Biochem; 2014 Oct; 47(15):126-9. PubMed ID: 25093923
[TBL] [Abstract][Full Text] [Related]
14. Reducing risk in thiopurine therapy.
Marinaki AM; Arenas-Hernandez M
Xenobiotica; 2020 Jan; 50(1):101-109. PubMed ID: 31682552
[TBL] [Abstract][Full Text] [Related]
15. Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT.
Park Y; Kim H; Seo H; Choi JY; Ma Y; Yun S; Min BJ; Seo ME; Yoo KH; Kang HJ; Im HJ; Kim JH
J Transl Med; 2020 Jul; 18(1):265. PubMed ID: 32611418
[TBL] [Abstract][Full Text] [Related]
16. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients.
Shah SA; Paradkar M; Desai D; Ashavaid TF
J Gastroenterol Hepatol; 2017 Mar; 32(3):620-624. PubMed ID: 27416873
[TBL] [Abstract][Full Text] [Related]
17. TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.
Grover N; Bhatia P; Kumar A; Singh M; Lad D; Mandavdhare HS; Samanta J; Prasad KK; Dutta U; Sharma V
BMC Gastroenterol; 2021 Aug; 21(1):327. PubMed ID: 34425754
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.
Sutiman N; Chen S; Ling KL; Chuah SW; Leong WF; Nadiger V; Tjai M; Choon Kong CS; Schwender BJ; Chan W; Shim HH; Lim WC; Khor CC; Cheung YB; Chowbay B
Pharmacogenomics; 2018 Jan; 19(1):31-43. PubMed ID: 29210335
[TBL] [Abstract][Full Text] [Related]
19. The effects of
Nghia H; Than HH; Dong CV; Oanh TTK; Truc VTT; Ngan CTT; Ngon HT; Binh NT; Dung PC; Anh Vu H; Xinh PT
Pediatr Hematol Oncol; 2022 Sep; 39(6):561-570. PubMed ID: 35156873
[TBL] [Abstract][Full Text] [Related]
20. NUDT15: A bench to bedside success story.
Moyer AM
Clin Biochem; 2021 Jun; 92():1-8. PubMed ID: 33675810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
